Sasan Sani, MD
Critical Care Medicine · Northridge, CANPI 1760702179
Payments from drug & device makers
Across 405 payments — averaging $666.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$202K
- Insmed, Inc.$32K
- Chiesi USA, Inc.$24K
- Intuitive Surgical$5K
- Pulmonx Corporation$1K
- GSK$1K
- plus $4K from 27 others
What the payments were for
- Travel & lodging$1,0948%
- Food & beverage$7,61357%
- Education$4,60535%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 68 | $202,242 |
| Insmed, Inc. | 45 | $31,756 |
| Chiesi USA, Inc. | 6 | $24,011 |
| Intuitive Surgical | 6 | $4,836 |
| Pulmonx Corporation | 9 | $1,316 |
| GSK | 62 | $1,140 |
| Bayer | 42 | $796 |
| Amgen | 36 | $662 |
| Regeneron Healthcare Solutions, Inc. | 26 | $648 |
| Boehringer Ingelheim | 20 | $461 |
| United Therapeutics Corporation | 15 | $386 |
| Actelion Pharmaceuticals US, Inc. | 18 | $345 |
| Advanced Respiratory, Inc | 8 | $165 |
| Philips North America LLC | 7 | $150 |
| Merck | 3 | $96 |
| Baxter Healthcare | 4 | $93 |
| Sanofi | 3 | $85 |
| Novartis | 4 | $77 |
| Resmed Corp | 2 | $74 |
| Grifols USA, LLC | 3 | $72 |
| Mylan Specialty L.p. | 2 | $51 |
| Electromed, Inc. | 3 | $46 |
| Pinnacle Biologics, Inc | 1 | $37 |
| Paratek Pharmaceuticals, Inc. | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Astellas Pharma US Inc | 1 | $26 |
| Verona Pharma, Inc. | 1 | $22 |
| AbbVie | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- Da Vinci Surgical System$1,745
- ZEPHYR ENDOBRONCHIAL VALVE$1,156
- TEZSPIRE$125
- NUCALA$120
How this compares
$269,771 in reported general payments places this provider in the 95th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 25 | $317,986 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 319 | $287,331 |
| TezspireTezepelumab-Ekko | 54 | $227,429 |
| AdempasRiociguat | 12 | $160,362 |
| OpsumitMacitentan | 13 | $151,938 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $96,324 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 68 | $55,637 |
| Breo ElliptaFluticasone/Vilanterol | 106 | $53,333 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 63 | $43,134 |
| Dupixent PenDupilumab | 12 | $42,286 |
| XolairOmalizumab | 12 | $39,388 |
| NucalaMepolizumab | 11 | $37,728 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 55 | $30,919 |
| Spiriva RespimatTiotropium Bromide | 25 | $17,211 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 273 | $11,073 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala | $1,140 | $421,525499 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $461 | $366,117105 claims |
| AstraZenecaTezspire, Breztri Aerosphere | $202,242 | $283,067122 claims |
| BayerAdempas | $796 | $160,36212 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $345 | $151,93813 claims |
| Grifols USA, LLCProlastin C | $72 | $96,32413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 715 critical care medicine providers in California.
Other critical care medicine in Northridge
- Rafael LupercioRedding$14.6M
- Timothy AlbertsonSacramento$7.6M
- Carolyn CalfeeSan Francisco$5M
- Bassam YaghmourOrange$4.4M
- Cedric Franklin RutlandRiverside$3.2M
- Alex HakimLos Angeles$946K
- Praveen AkuthotaSan Diego$841K
- Wael El MaraachliSan Diego$751K
- Stephen RuossStanford$635K
- Bryon QuickOakland$594K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.